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Abstract
Background: Emphysema on CT is common in older smokers. We hypothesised that emphysema on CT predicts acute
episodes of care for chronic lower respiratory disease among older smokers.
Materials and Methods: Participants in a lung cancer screening study age $60 years were recruited into a prospective
cohort study in 2001–02. Two radiologists independently visually assessed the severity of emphysema as absent, mild,
moderate or severe. Percent emphysema was defined as the proportion of voxels # 2910 Hounsfield Units. Participants
completed a median of 5 visits over a median of 6 years of follow-up. The primary outcome was hospitalization, emergency
room or urgent office visit for chronic lower respiratory disease. Spirometry was performed following ATS/ERS guidelines.
Airflow obstruction was defined as FEV1/FVC ratio ,0.70 and FEV1,80% predicted.
Results: Of 521 participants, 4% had moderate or severe emphysema, which was associated with acute episodes of care
(rate ratio 1.89; 95% CI: 1.01–3.52) adjusting for age, sex and race/ethnicity, as was percent emphysema, with similar
associations for hospitalisation. Emphysema on visual assessment also predicted incident airflow obstruction (HR 5.14; 95%
CI 2.19–21.1).
Conclusion: Visually assessed emphysema and percent emphysema on CT predicted acute episodes of care for chronic
lower respiratory disease, with the former predicting incident airflow obstruction among older smokers.
Citation: McAllister DA, Ahmed FS, Austin JHM, Henschke CI, Keller BM, et al. (2014) Emphysema Predicts Hospitalisation and Incident Airflow Obstruction among
Older Smokers: A Prospective Cohort Study. PLoS ONE 9(4): e93221. doi:10.1371/journal.pone.0093221
Editor: Neeraj Vij, Central Michigan University School of Medicine, United States of America
Received February 14, 2013; Accepted March 4, 2014; Published April 3, 2014
Copyright:  2014 McAllister et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Collection of spirometric and percent emphysema measures, longitudinal components from the third visit onwards, and analysis and interpretation of
the data were supported via grants R01-HL075476, R01-HL077612, R01-HL093081, RR024156, and ES09089 from the National Institutes of Health. The baseline and
second visits were funded by the City of New York Department of Health and Mental Hygiene; the Starr Foundation; Empire Blue Cross and Blue Shield; the New
York Community Trust; New York State Office of Science, Technology, and Academic Research; the Rogers Family Fund; Weill Medical College of Cornell University;
Cornell University; and AMDeC Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have the following interests: DY, AR, and CH are named inventors on the following patents and patent applications relating
to the evaluation of diseases of the chest including measurement of nodules: 7274810 (System and method for three-dimensional image rendering and analysis),
7499578 (System, method and apparatus for small pulmonary nodule computer aided diagnosis from computed tomography scans), 7693729 (System and
method for conducting a clinical trial study),7751607 (System, method and apparatus for small pulmonary nodule computer aided diagnosis from computed
tomography scans), 8045770 (System and method for three-dimensional image rendering and analysis), 8050481 (Method and apparatus for small pulmonary
nodule computer aided diagnosis from computed tomography scans), 8165385 (System and method for three-dimensional image rendering and analysis),
8577129 (System and method for three-dimensional image rendering and analysis). Some of these, which are owned by Cornell Research Foundation (CRF) are
nonexclusively licensed to General Electric. As an inventor of these patents, DY, AR, and CH are entitled to a share of any compensation which CRF may receive
from its commercialization of these patents. As of April 2009, CH has signed away any financial benefit including royalties and any other proceeds related to the
patents or patent applications. SV is currently employed by GSK but exclusively performed the work while an employee of Columbia University. This study was
partly funded by Empire Blue Cross and Blue Shield. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: rgb9@columbia.edu
Introduction
Chronic obstructive pulmonary disease (COPD) is the fourth
leading cause of death worldwide [1] and chronic lower
respiratory disease (CLRD), which comprises COPD, pulmonary
emphysema, chronic bronchitis and asthma, recently overtook
stroke as the third leading cause of death in the United States. [2].
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Pulmonary emphysema is a common finding on computed
tomography (CT) among older smokers. Approximately 25% of
older smokers undergoing lung cancer screening,[3–5] 12% of
patients investigated for pulmonary embolism, [6] and 4% of
patients undergoing cardiac CT scans have detectable emphysema
on CT. [7] Given that lung cancer CT screening has recently been
found to improve lung cancer survival among smokers, [8]
pulmonologists are likely to encounter emphysema on CT in
increasing numbers of patients.
Emphysema assessed quantitatively or visually on CT scans is
correlated with airflow obstruction on spirometry [9–14] but also
occurs in the absence of spirometrically defined COPD, for
example, in a recent large multi-centre study of patients with
COPD, radiologists identified mild to moderate emphysema in
8.5% of the control group, which comprised smokers with normal
spirometry. [15].
Emphysema on CT predicts all-cause mortality and death from
COPD and lung cancer [16–18]. Emphysema also predicts decline
in pulmonary function in both COPD [19] and in male older
current and former heavy smokers [20], but did not independently
predict exacerbations in a large prospective study of mostly severe
COPD. [21] However, whether quantitative and qualitative
measures of emphysema predict acute episodes of care for lower
respiratory diseases among older smokers is unknown.
We therefore examined whether visual and quantitative
measures of emphysema on CT independently predicted acute
episodes of care for CLRD and decline in lung function in a
prospective cohort study of older current or former smokers
undergoing CT screening for lung cancer.
Methods
We enrolled all 557 participants at one site of a lung cancer CT
screening study in 2001–2002. [22] Inclusion criteria were $10
pack-years of cigarette smoking, age 60 years and older,
willingness to undergo screening for lung cancer, and no cancer
history except non-melanoma skin cancer. Thirty-six (6%)
participants were missing percent emphysema measures due to
irretrievable scans; therefore 521 participants were included.
The baseline and annual follow-up visits included a CT scan,
spirometry, and assessment of acute episodes of CLRD and
potential confounders. Annual follow-up visits continued through
July 01, 2009.
The Institutional Review Board of Columbia University and the
Western Institutional Review Board approved all study activities
and all participants provided written informed consent.
Emphysema on CT Scan
All participants underwent low-dose, non-contrast, full-lung CT
scanning on a single Siemens 4-slice multidetector scanner in
2001–02 (140 kVp, 43 mAs, 10-mm thickness, B50f reconstruc-
tion kernel, contiguous slices from the thoracic inlet to the
adrenals) in a protocol consistent with the National Lung Cancer
Screening trial. [23].
Qualitative visual emphysema assessment. Two board-
certified academic chest radiologists read all sections of all scans
prior to reviewing participant information and without percent
emphysema scores; 61% of scans were re-read a third time.
Emphysema was graded as none, mild, moderate or severe. The
intra-observer and inter-observer agreement by weighted Kappa
score were 0.91 and 0.72 respectively. Agreement in distinguishing
moderate or severe emphysema from no emphysema was excellent
(Kappa= 0.95) whereas agreement in distinguishing mild emphy-
sema from none was modest (Kappa= 0.65). Where readers
disagreed, the majority opinion was taken except in 27 discordant
cases with two reads only, for which the earlier read was used.
Quantitative percent emphysema. The percentage of
emphysema-like lung, hereafter referred to as percent emphysema,
was defined as the proportion of full lung volume with attenuation
# –910 Hounsfield Units (HU). [13] To correct for interscan
variation in air attenuation, we modified the base threshold using
the attenuation of tracheal air.
Acute Episodes of Care for CLRD
Definition. Acute episodes of care for CLRD were identified
via questionnaire at annual follow-up visits. Participants were
asked the number of times that they had been hospitalized or had
an urgent clinic or emergency room visit for COPD, bronchitis,
emphysema or asthma. Acute episodes were defined as the sum of
urgent office visits, emergency room visits and hospitalizations.
[24].
Electronic medical records. Since self-reported acute
episodes relied upon completeness of follow-up, we also identified
these from electronic medical records for all 214 participants
whose primary doctor was affiliated with Columbia University
Medical Center or who resided in zip codes adjacent to the
hospital. Acute episodes were defined as hospitalizations, emer-
gency room visits, and clinic attendances assigned a primary or
secondary diagnostic code of acute exacerbation of COPD or
asthma (ICD-9 CM 491.21, 491.22, 493.02, 493.21, 493.22, or
493.92). Hospitalizations for any respiratory disease (ICD-9 CM
460 to 519) were also identified. Repeat episodes within 13 days
were treated as single events. [25].
Spirometry
Spirometry was performed in 2001–02 and annually thereafter
according to American Thoracic Society (ATS) guidelines [26]
using the EasyOne Diagnostic spirometer (ndd Medical Technol-
ogies, Chelmsford, MA), which we have previously validated. [27]
Measurements were reviewed by a physician and spirometry
quality was defined using 2005 ATS/European Respiratory
Society (ERS) recommendations. [28] Airflow obstruction was
defined as a FEV1/forced vital capacity (FVC) ratio ,0.70 and
FEV1,80% predicted. [29] NHANES prediction equations were
used.
Covariate Data
Information on age, sex, race/ethnicity, educational attainment,
clinical diagnoses, medication and healthcare insurance status was
recorded by interviewer-administered questionnaire at baseline
and follow-up visits. Suspected chronic lower respiratory disease at
baseline was defined as self-reported COPD, asthma, emphysema
or chronic bronchitis or prescriptions of inhaled beta-agonists,
anticholinergics or corticosteroids, or methylxanthines. Body mass
index (BMI) was calculated as weight (kg) divided by height
squared (m2). Smoking status was verified by urinary cotinine
levels, ascertained using enzyme-linked immunosorbent assay
(Orasure Technologies, Inc., Bethlehem, PA).
Statistical Analysis
Baseline characteristics were compared across quartiles of
percent emphysema. Initial stratum-specific rate ratios (RR) were
calculated as the number of acute episodes of care divided by the
years from the baseline visit to last follow-up. Multivariate RRs for
all acute episodes and for hospitalizations were estimated using
generalized linear models with a Poisson distribution. Rates were
weighted for follow-up time and standard errors were corrected for
Emphysema, Hospitalizations & Airflow Obstruction
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Table 1. Baseline characteristics by CT percent emphysema quartiles.
Q1 Q2 Q3 Q4
Number of participants 130 131 129 131
Median percent emphysema, % 9 20 31 47
Age, mean (SD), years 66 (6) 66 (4) 68 (5) 68 (6)
Gender – male, n (%) 55 (42) 77 (59) 74 (57) 60 (46)
Race/Ethnicity, n (%)
Caucasian 87 (67) 93 (71) 94 (73) 111 (85)
African-American 17 (13) 13 (10) 10 (8) 5 (4)
Hispanic 18 (14) 13 (10) 8 (6) 7 (5)
Chinese 9 (7) 12 (9) 17 (13) 8 (6)
Height, mean (SD), cm 168 (9) 170 (10) 170 (10) 169 (10)
Weight, mean (SD), kg 76 (15) 80 (16) 78 (15) 72 (15)
BMI, mean (SD), kg/m2 27 (5) 27 (5) 27 (5) 25 (4)
BMI ,25 kg/m2, n (%) 51 (39) 46 (35) 48 (37) 73 (56)
BMI 25 to 30 kg/m2, n (%) 49 (38) 50 (38) 48 (37) 45 (34)
BMI .30 kg/m2, n (%) 30 (23) 35 (27) 34 (26) 13 (10)
Educational Attainment, n (%)
Graduate Degree 31 (24) 25 (19) 40 (31) 41 (31)
Batchelor Degree 38 (29) 37 (28) 36 (28) 34 (26)
High School/some College 48 (37) 58 (44) 44 (34) 50 (38)
No High School Diploma 13 (10) 10 (8) 9 (7) 7 (5)
Healthcare Insurance, n (%)
Private 74 (57) 64 (49) 71 (55) 77 (59)
Medicare 31 (24) 47 (36) 31 (24) 41 (31)
Other Government 12 (9) 10 (8) 12 (9) 9 (7)
None 12 (9) 8 (6) 15 (12) 4 (3)
Diagnosis of, n (%)
Asthma 13 (10) 18 (14) 6 (5) 20 (15)
Emphysema or chronic bronchitis 7 (5) 17 (13) 17 (13) 25 (19)
Acute episode of care for CLRD, n (%) 9 (7) 8(6) 4(3) 16(13)
Respiratory symptoms, n (%)
MRC Chronic Bronchitis 29 (22) 28 (21) 23 (18) 26 (20)
MRC Grade 3 Dyspnea or worse 12 (9) 8 (6) 13 (10) 14 (11)
Smoke Exposure
Current Smoker, n (%) 73 (56) 60 (46) 35 (27) 47 (36)
Pack Years, median (IQR) 46 (36–67) 48 (34–63) 44 (28–65) 41 (27–59)
Cotinine, median (IQR), ng/ml 967 (25–2047) 90 (20–1583) 32 (11–291) 62 (19–1216)
Spirometry
FEV1 percent predicted, mean (SD), % 80 (18) 82 (18) 81 (21) 76 (23)
FVC percent predicted, mean (SD), % 85 (18) 89 (18) 90 (18) 88 (19)
FEV1/FVC ratio, mean (SD),% 72 (8) 70 (9) 68 (10) 65 (12)
FEV1/FVC ratio ,0.70
and FEV1,80% predicted, n (%)
33 (25) 38 (29) 52 (40) 63 (48)
Visual emphysema assessment, n (%)
None 103 (79) 106 (81) 99 (77) 94 (72)
Mild 26 (20) 17 (13) 26 (20) 26 (20)
Moderate or Severe 1 (1) 8 (6) 4 (3) 10 (8)
FEV1 - forced expiratory volume in one second, FVC - forced vital capacity, CLRD – chronic lower respiratory disease (includes any of asthma, COPD, chronic bronchitis
and emphysema).
doi:10.1371/journal.pone.0093221.t001
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overdispersion. [30] Initial models adjusted for the confounders of
age, sex, and race/ethnicity and full models additionally adjusted
for pack years, cotinine at time of CT, private healthcare
insurance (as a marker of socioeconomic status) and suspected
chronic lower respiratory disease. We separately report associa-
tions additionally adjusted for pulmonary function (FEV1 and the
FEV1/FVC ratio) as in the majority of clinical settings spirometry
is unlikely to have been performed prior to CT lung cancer
screening on all patients.
To ensure that these findings are not solely the result of a small
number of participants experiencing multiple recurrent events, we
performed secondary analyses for time-to-first-event using hazard
ratios (HR) in Cox proportional hazards models.
The relationship of emphysema at baseline to change in FEV1
was assessed with linear mixed models adjusting for age, sex, race/
ethnicity, height, height2, weight, weight2, smoking status and pack
years at baseline, and urinary cotinine levels. These models
accommodate variable follow-up times assuming missing-at-
random, in other words, that the missing data is not related to
emphysema conditional on the information in the model. In Cox-
proportional hazard models we also estimated the instantaneous
risk of testing positive for airflow obstruction on follow-up
spirometry where it was not present at baseline.
Missing covariate data were uncommon. Six respondents aged
,65 years with missing healthcare insurance data were assumed to
be uninsured and, in 4 participants without urinary cotinine, the
sample median was used.
Analyses were performed using SAS version 9.2 (SAS Institute,
Cary, NC) and R version 2.14.2 (R Foundation for Statistical
Computing, Vienna, Austria).
Results
The mean age of the 521 participants was 67 years at baseline,
51% were male and 42% were current smokers. Eighteen percent
had mild and 3% had moderate or severe emphysema assessed
visually on CT scan. Thirty-six percent had airflow obstruction on
spirometry.
Participants with higher percent emphysema had lower lung
function, greater dyspnea and more self-reported COPD than
participants with less percent emphysema (Table 1). Moderate or
severe emphysema on visual assessment increased across quartiles
of percent emphysema. Visual emphysema assessment and percent
emphysema were moderately correlated (r = 0.10, P= 0.02) but
were both associated with the FEV1/FVC ratio (r =20.28; P,
0.001 and r =20.31, P,0.001 respectively).
The 521 participants completed a median of 5 visits over a
median of 6 years of follow-up. Twenty-four died without
attending follow-up and 384 (77%) completed at least one
follow-up visit, with 324 (65% overall and 84% of those with
one or more follow-up visits) completing a visit 5 or more years
after baseline. Percent emphysema and baseline lung function
were similar in those with and without follow-up.
Table 2. Episodes of chronic lower respiratory disease by category of emphysema visually.
No
emphysema
Mild
emphysema
P
Value
Moderate to
severe
emphysema
P
Value
Number of participants 402 95 23
Acute episodes of care
Number of episodes 234 28 25
Total follow-up time (years) 1488 334 75
Number of episodes per ten person years 1.57 0.84 3.33
Rate Ratio
Model 1 1 0.56 (0.31–1.01) 0.06 1.89 (1.01–3.52) 0.046
Model 2 1 0.61 (0.34–1.10) 0.10 1.58 (0.83–2.99) 0.16
Hospitalization
Number of hospitalizations 37 7 7
Total follow-up time (years)Total follow-up time (years) 1488 334 75
Number of hospitalizations per ten person years 0.02 0.02 0.09
Rate Ratio
Model 1 1 0.82 (0.44–1.54) 0.55 2.90 (1.56–5.42) ,0.001
Model 2 1 1.11 (0.59–2.07) 0.75 2.17 (1.11–4.24) 0.02
Airflow obstruction on follow-up spirometry
Number of participants who developed airflow obstruction over follow-up 56 46 7
Number of participants without airflow obstruction at baseline 293 15 9
Model 1 1 1.85 (1.04–3.28) 0.04 7.29 (3.25–16.4) ,0.001
Model 2 1 1.44 (0.79–2.62) 0.23 5.14 (2.19–12.1) ,0.001
Model 1 adjusted for age, sex and race/ethnicity.
Model 2 additionally adjusted for pack years smoking, cotinine at time of CT, private healthcare insurance and suspected chronic lower respiratory disease.
One person who had percent emphysema measured did not have emphysema assessed visually.
doi:10.1371/journal.pone.0093221.t002
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Acute Episodes of Care for CLRD
Ninety participants reported 287 episodes of urgent care, with
29 reporting 51 hospitalizations, over 1,897 person-years of follow-
up for mean rates of 15.1 acute episodes and 2.7 hospitalizations
per hundred person-years. Of the 90 participants, 78 had self-
reported COPD, asthma, emphysema or chronic bronchitis or
prescriptions of inhaled beta-agonists, anticholinergic or cortico-
steroids, or methylxanthines. Of these 20 had airflow obstruction
at baseline and 15 subsequently had airflow obstruction on follow-
up spirometry.
Adjusting for age, sex, race/ethnicity, cotinine, healthcare
insurance, height and history of known COPD, compared to
participants without airflow obstruction, rates for acute episodes of
care were higher for participants with FEV1 percent predicted 50
to 79% (RR 1.60; 95% CI: 1.03–2.47; P = 0.03) and for
participants with FEV1 percent predicted less than 50% (RR
3.38; 95% CI: 1.91–6.00; P,0.001). Adjusting for the same
covariates, higher rates were also found for hospitalisation for
participants with FEV1 percent predicted 50 to 79% (RR 3.82;
95% CI: 2.18–6.69; P,0.001) and for participants with FEV1
percent predicted less than 50% (RR 4.52; 95% CI: 2.08–9.87;
P,0.001).
Visual Emphysema Assessment
Acute episodes of care for CLRD. Moderate to severe
emphysema on visual assessment was associated with acute
episodes of care (RR 1.89; 95% CI: 1.01–3.52; P= 0.046) and
hospitalisation (RR 2.90; 95% CI: 1.56–5.42; P,0.001) adjusting
for age, sex and race/ethnicity (Table 2). After additional
adjustment for pack years smoking, cotinine at time of CT,
private healthcare insurance and suspected chronic lower respi-
ratory disease the associations for both acute episodes of care (RR
1.58; 95% CI: 0.83–2.99; P= 0.16) and hospitalisation (RR 2.17;
95% CI: 1.11–4.24; P= 0.02) were attenuated, although the latter
remained statistically significant. The associations were strongly
attenuated by the inclusion of pulmonary function at baseline (RR
1.09; 95% CI 0.58–2.05; P= 0.78 and RR 1.61; 95% CI: 0.83–
3.14; P= 0.16 respectively). Mild emphysema on visual assessment
was not associated with acute episodes of care or hospitalisation.
Decline in lung function. When pulmonary function was
modeled as a continuous variable neither mild nor moderate to
severe emphysema predicted decline in FEV1 (2 ml per year; 95%
CI 221 to 24 and 1 ml per year; 95% CI 213 to 11 respectively,
P= 0.98). Findings were similar for decline in the FEV1/FVC
ratio, FEV1 percent predicted and proportional change in FEV1
(P= 0.98, P= 0.95 and P= 0.20 respectively).
However, among participants without airflow obstruction at
baseline (Table 2), moderate to severe emphysema was associated
with increased risk of airflow obstruction on follow-up spirometry
after adjusting for age, sex and ethnicity (HR 7.29; 95% CI 3.25–
16.4;P,0.001) and after pack years smoking, cotinine at time of
CT, private healthcare insurance and suspected chronic lower
respiratory disease (HR 5.14; 95% CI 2.19–21.1; P,0.001).
Weaker associations in the same direction were observed for mild
emphysema.
Percent Emphysema
Acute episodes of care for CLRD. Percent emphysema also
predicted acute episodes of care (Table 3, Figure 1). Participants in
the highest quartile of percent emphysema had approximately
twice the rate as those in the lowest quartile (RR 2.40; 95% CI:
1.37–4.21) and more than three times the rate of hospitalization
for CLRD (RR 3.50; 95% CI: 1.69–7.24). Associations were
attenuated by approximately 10% after adjusting for height, FEV1
and FEV1/FVC ratio but the association persisted.
The association for percent emphysema was not modified by
including emphysema assessed visually in the model (RR 1.33;
95% CI: 1.11–1.60; P= 0.002).
Similar results were obtained when time to first episode was
modeled in cox-proportional hazard models.
Decline in lung function. Percent emphysema was not
associated with airflow obstruction on follow-up spirometry (HR
1.05 per one SD; 0.84–1.33; P= 0.66). Nor did percent
emphysema predict differences in the decline of FEV1 (21 ml/
year per SD increment in percent emphysema, 95%CI 26 to 4,
P= 0.62) nor incident airflow obstruction.
Figure 1. Cumulative incidence plot of time to first episode by percent emphysema.
doi:10.1371/journal.pone.0093221.g001
Emphysema, Hospitalizations & Airflow Obstruction
PLOS ONE | www.plosone.org 5 April 2014 | Volume 9 | Issue 4 | e93221
Additional Analyses
Among 214 local participants for whom electronic medical
records were available, there were 28 episodes of care for CLRD
and 21 admissions for any respiratory disease over 1,540 person-
years. Percent emphysema predicted episodes of care (multivariate
RR 1.45; 95% CI: 1.04–2.03; P= 0.03) and respiratory admissions
(multivariate RR 1.62; 95% CI: 1.08–2.44; P= 0.02) adjusting for
age, sex, race/ethnicity and cotinine at time of CT scan.
Discussion
In older smokers undergoing lung cancer screening, patients
with moderate or severe emphysema on CT scan had a two-fold
increased rate of hospitalization for CLRD after adjustment for
smoking and other potential confounders over a median of six
years of follow-up. Quantitative percent emphysema was associ-
ated with an increased rate for acute episodes of care and
hospitalization for CLRD.
The present study adds to the literature by demonstrating strong
relationships of both qualitatively and quantitatively defined
emphysema on CT scan to hospitalisation for CLRD in a
prospective cohort study of older smokers with and without
COPD. No prior studies of which we have aware have reported
this association for radiologist-defined pulmonary emphysema,
which is the clinically relevant measure of pulmonary emphysema
and which could assist in risk-stratification of smokers.
Qualitatively and quantitatively defined emphysema were only
weakly correlated with each other, although both were similarly
associated with the FEV1/FVC ratio at baseline, and percent
emphysema continued to predict acute episodes of care and
hospitalisations for CLRD after adjusting for emphysema on visual
assessment. As such qualitative and quantitative emphysema
measures may provide complementary clinical information.
The present longitudinal results for percent emphysema are
consistent with and build upon those of a prior large cross-
sectional study of patients with COPD [31] but are at variance
with those of a large longitudinal study of patients with COPD.
[21] The latter study, however, enrolled patients predominantly
with severe COPD and 47% of enrolled participants reported an
exacerbation in the year prior to enrolment, compared to 17% in
the cross-sectional study and 8% in the present study. The present
findings for both percent emphysema and visually assessed
emphysema remained significant after adjustment for prior
exacerbations. These divergent results suggest that emphysema
on CT scan may predict clinically important events among
patients with milder and no COPD but do not predict
eventsindependently of frequent exacerbations among patient
with severe COPD.
Two recent large studies demonstrated that emphysema
predicted a small but statistically significant accelerated decline
in the FEV1 [19,20] (13 ml and 27 ml per year respectively). We
also found that compared to participants without emphysema on
CT, those participants with moderate to severe emphysema had a
five-fold increased risk of new airflow obstruction on follow-up
spirometry, with similar but weaker associations for mild
emphysema. This finding persisted after adjusting for smoking
and additional potential confounders. However, caution is needed
in interpreting our finding in view of the small numbers with
moderate to severe emphysema, and because we did not find that
emphysema predicted decline in lung function in our primary
analysis.
There has been recent interest in strategies for case-finding to
reduce harms and costs associated with hospitalisation. [32] Our
Table 3. Episodes of chronic lower respiratory disease by category of percent emphysema.
Q1 Q2 Q3 Q4
One SD Change in CT
Percent Emphysema P Value
Number of participants 130 131 129 131
Acute episodes of care
Number of episodes 49 88 72 78
Total follow-up time (years) 463 477 515 442
Number of episodes per ten person years 1.06 1.84 1.40 1.76
Rate Ratio
Model 1 1 2.04 1.64 2.40 1.29 (1.08–1.55) 0.006
Model 2 1 1.81 1.58 2.49 1.33 (1.11–1.60) 0.002
Number of participants with $1 episode of care 16 22 27 25
Hazard Ratio for first episode
Model 1 1 1.69 1.96 2.15 1.32 (1.07–1.63) 0.008
Model 2 1 1.63 1.89 2.30 1.35 (1.09–1.68) 0.005
Hospitalizations
Number of hospitalizations 7 19 13 12
Total follow-up time (years) 463 477 515 442
Number of hospitalizations per ten person years 0.15 0.40 0.25 0.27
Rate Ratio
Model 1 1 3.36 1.78 3.50 1.44 (1.15–1.80) 0.002
Model 2 1 3.03 1.99 3.54 1.47 (1.19–1.81) ,0.001
Model 1 adjusted for age, sex and race/ethnicity.
Model 2 additionally adjusted for pack years smoking, cotinine at time of CT, private healthcare insurance and suspected chronic lower respiratory disease.
doi:10.1371/journal.pone.0093221.t003
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findings and those of Hoesein et al [20] suggest that consideration
should be given to COPD case-finding among older smokers with
emphysema identified on CT lung cancer screening, since not only
was airflow obstruction common both at baseline and subsequent-
ly, but subsequent hospitalisation for CLRD was also commoner
among this group. Studies in this group of patients investigating
the efficacy and cost-effectiveness of spirometry for preventing
hospitalisation are needed.
Limitations
Follow-up in this eight-year study of smokers was incomplete,
leading to a likely underestimation of the rates of acute episodes of
care, hospitalization and decline in lung function. However,
follow-up did not differ by category of percent emphysema, and
percent emphysema predicted acute episodes and hospitalization
in a subset where these outcomes were identified via electronic
medical records; therefore, the results are unlikely to be the result
of differential follow-up. Radiologists did not follow a published
protocol such as that of the National Emphysema Treatment Trial
(NETT) to grade emphysema. [33] Although this may have
reduced precision, reproducibility for moderate or severe emphy-
sema was high and this approach likely increased clinical
applicability since the interpretations followed standard academic
clinical practice. Moreover, using an identical method this group
of radiologists found that mild, moderate and severe emphysema
predicted lung cancer and mortality from COPD in older smokers
undergoing CT lung cancer screening. [16] An additional
limitation was that reproducibility for mild emphysema was not
high. Therefore, it is unclear if mild emphysema failed to predict
clinical events because it is truly of no clinical significance or
because of the imprecision of the measure. The results for percent
emphysema make the latter more likely, in our opinion.
Although both qualitatively and quantitatively defined emphy-
sema were statistically significantly associated with hospitalisation
for CLRD, only the latter was associated for all acute episodes of
care for CLRD. However, the observed associations were similar
across hospitalisation and all acute episodes of care for both
measures, and as such we suggest that that the most likely
explanation for the lack of statistical significance for moderate to
severe emphysema on visual assessment is the lower precision of
‘‘all episodes’’ as an outcome measure compared to ‘‘hospitalisa-
tion’’.
Lung function was measured without a bronchodilator, which
reduced precision. However, the mean decline in the FEV1 was
similar to that reported for pre-bronchodilator spirometry in the
UPLIFT trial in COPD. [34].
In conclusion, both radiologist-determined and quantitatively
defined pulmonary emphysema on CT scan independently
predicted hospitalizations for CLRD with the former also
predicting incident airflow limitation in a general sample of older
smokers.
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